The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Targeting BCLxL in MPNs: current perspectives and future outlooks
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses targeting the BCLxL pathway for the development of novel agents in myeloproliferative neoplasms (MPNs). A Phase I/II trial showed that the BCLxL inhibitor navitoclax, in combination with the JAK inhibitor ruxolitinib, demonstrated encouraging clinical efficacy and safety. However, in the subsequent Phase III trial (NCT04472598), while the primary endpoint of spleen volume reduction (SVR35) was met, the secondary endpoint of reduced symptom burden (total symptom score; TSS) was not achieved. In the future, Dr Pemmaraju emphasizes the importance of exploring other BCLxL inhibitors that can achieve both endpoints and be used as a suitable therapy for treating MPNs. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Membership on Board of Directors/Advisory Committees: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, Dan’s House of Hope, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Speakers Bureau: ClearView Healthcare Partners, Imedex, EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals; Research Funding: United States Department of Defense (DOD), National Institute of Health/National Cancer Institute (NIH/NCI); Licenses: Karger Publishers; Leadership role on ASH Committee on Communications and ASCO Cancer.Net Editorial Board.
